Search results
Apr 17, 2024 · Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum. April 26, 2024 Lilly Recommends Shareholders Reject “Mini-Tender” Offer by Tutanota LLC. April 22, 2024 Lilly Acquires New Injectable Medicine Manufacturing Facility from Nexus Pharmaceuticals
2 days ago · Lilly recalculates current period figures on a constant currency basis by keeping constant the exchange rates from the base period. The company's 2024 financial guidance is provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business.
Current Medicines. For more than 140 years, we have worked tirelessly to develop and deliver trusted medicines and diagnostics that meet real needs. Our growing portfolio of medicines includes treatments in the areas of bone muscle joint, cancer, cardiovascular, diabetes, endocrine, immunology, neurodegeneration, neuroscience, and pain.
As of 2022, Lilly is known for its clinical depression drugs Prozac ( fluoxetine) (1986), Cymbalta ( duloxetine) (2004), and its antipsychotic medication Zyprexa ( olanzapine) (1996), although its primary revenue drivers are the diabetes drugs Humalog ( insulin lispro) (1996) and Trulicity ( dulaglutide) (2014). [5]
For more than 90 years, Lilly has been committed to diabetes and meeting the needs of people affected by diabetes with treatment options, support programs and more.
2 days ago · April 30 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares ...
2 days ago · Eli Lilly Stock Jumps After Weight-Loss Drug Sales Soar. Eli Lilly stock rose after the drug maker reported a 26% increase in quarterly revenue, aided by robust demand for its weight-loss drug ...
